Functionally Competent Eosinophils Differentiated Ex Vivo in High Purity from Normal Mouse Bone Marrow

Kimberly D. Dyer, Jennifer M. Moser, Meggan Czapiga, Steven J. Siegel, Caroline M. Percopo and Helene F. Rosenberg

*J Immunol* 2008; 181:4004-4009; doi: 10.4049/jimmunol.181.6.4004
http://www.jimmunol.org/content/181/6/4004

References

This article cites 40 articles, 14 of which you can access for free at:
http://www.jimmunol.org/content/181/6/4004.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
We have devised an ex vivo culture system which generates large numbers of eosinophils at high purity (>90%) from unselected mouse bone marrow progenitors. In response to 4 days of culture with recombinant mouse FLT3-L and recombinant mouse stem cell factor followed by recombinant mouse IL-5 alone thereafter, the resulting bone marrow-derived eosinophils (bmEos) express immunoreactive major basic protein, Siglec F, IL-5R α-chain, and transcripts encoding mouse eosinophil peroxidase, CCR3, the IL-3/IL-5/GM-CSF receptor common β-chain, and the transcription factor GATA-1. BmEos are functionally competent: they undergo chemotaxis toward mouse eotaxin-1 and produce characteristic cytokines, including IFN-γ, IL-4, MIP-1α, and IL-6. The rodent pathogen pneumonia virus of mice replicates in bmEos and elevated levels of IL-6 are detected in supernatants of bmEos cultures in response to active infection. Finally, differentiating bmEos are readily transfected with lentiviral vectors, suggesting a means for rapid production of genetically manipulated cells. The Journal of Immunology, 2008, 181: 4004–4009.

Materials and Methods

Isolation and ex vivo culture of mouse bone marrow-derived eosinophils (bmEos)

Bone marrow cells were collected from the femurs and tibiae of wild-type BALB/c mice (Taconic Farms) by flushing the opened bones with IMDM (Invitrogen). RBC were lysed in dH2O followed by the addition of 10× PBS. After centrifugation, the cells were washed once in PBS containing 0.1% BSA. The bone marrow cells were cultured at 10^6/ml in medium containing RPMI 1640 (Invitrogen) with 20% FBS (Cambrex), 100 IU/ml penicillin and 10 µg/ml streptomycin (Cellgro), 2 mM glutamine (Invitrogen), 25 mM HEPES and 1× nonessential amino acids and 1 mM sodium pyruvate (Life Technologies), and 50 µM 2-ME (Sigma-Aldrich) supplemented with 100 ng/ml stem cell factor (SCF; PeproTech) and 100 ng/ml FLT3 ligand (FLT3-L; PeproTech) from days 0 to 4. On day 4, the medium containing SCF and FLT3-L was replaced with medium containing 10 ng/ml recombinant mouse (m) IL-5 (R&D Systems) only. On day 8, the cells were moved to new flasks and maintained in fresh medium supplemented with mIL-5. Every other day, from this point forward, one-half of the medium was replaced with fresh medium containing mIL-5, and the
concentration of the cells was adjusted each time to 10^6/ml. Cells were enumerated at day 0 and on days indicated thereafter in a hemocytometer, and 50,000 cells were subjected to cytospin (Thermo Shandon). The cytospin preparations were fixed and stained using a modified Giemsa preparation (Diff Quik).

Isolation of RNA from bmEos and quantitative RT-PCR

Mouse bmEos were suspended in RNAzol B (Tel-Test) at a concentration of 1 ml/10^6 cells and extraction proceeded as per the manufacturer’s instructions. The precipitated RNA was harvested by centrifugation, washed in 70% ethanol, dried, and suspended in sterile diethyl pyrocarbonate (DEPC)-treated water. Two micrograms of RNA prepared as described was subjected to DNase I treatment (Invitrogen) and reverse transcribed using a First Strand cDNA Synthesis Kit for RT-PCR (avian myeloblastosis virus reverse transcriptase; Roche Diagnostics). One microlitr of cDNA was subjected to TaqMan (Q) PCR using a FAM-labeled probe and primers to each indicated mouse gene. All primer probe sets were purchased from Applied Biosystems (eicosinophil peroxidase (EPO), Mm00514768_m1; major basic protein (MBP), Mm00435905_m1; GATA3, Mm00484683_m1; IL-5R, Mm00434273_m1; GMCSFR, Mm00433311_g1; common β-chain, Mm00655745_m1; CCR3, Mm00515543_s1; and MPO, Mm00478866_m1). All experiments included a no reverse transcriptase and no-template control and mouse GAPDH (ABT no. 430353) was used as the endogenous control. Transcripts at each time point are normalized to GAPDH to account for variations in initial template concentration and then reported relative to expression at day 0. Values are mean ± SEM of cultures derived from mice.

Flow cytometric analysis of bmEos surface proteins

Cells derived from ex vivo culture of mouse bone marrow were probed with the indicated Ab or isotype control in PBS with 0.1% BSA for 30 min at 4°C. After staining, the cells were washed with PBS with 0.1% BSA, fixed in 4% paraformaldehyde, and analyzed by flow cytometry. Data were acquired with a FACSCalibur flow cytometer (BD Biosciences) and analyzed with FlowJo software version 7.1 (Tree Star). Positive cells were identified by comparison to the appropriately conjugated isotype control. Abs (all from BD Pharmingen) were used included PE-conjugated rat anti-mouse Siglec F or PE-conjugated IgG2a Isotype control, allophycocyanin-conjugated anti-mouse Gr-1/Ly-6C, Alexa Fluor 488-conjugated anti-mouse IL-5R/CD125, and PE-conjugated anti-mouse CD11b.

Immunostaining and observation of bmEos by confocal microscopy

One million bmEos were washed with 3 ml of 0.1% BSA in PBS (BSA/ PBS) and then fixed and permeabilized with FIX & PERM (Caltag Laboratories) per the manufacturer’s protocol or by fixing in 4% paraformaldehyde followed by permeabilization in ice-cold methanol. Rabbit anti-MBP (no. 509 was a gift from Dr. N. A. Lee and Dr. J. J. Lee) was used at 1/5000 for 1 h at 4°C. The cells were washed in BSA/PBS, and an Alexa Fluor 647-conjugated secondary Ab goat anti-rabbit IgG-Alexa Fluor 647 Ab (Molecular Probes) was applied at a 1/100 dilution. After a 1-h incubation in the dark at room temperature, the cells were washed and the nuclear stain, 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI; Molecular Probes) was added at 1 μg/ml and incubated for 15 min in the dark. The cells were washed twice in BSA/PBS and then fixed onto glass slides using cytoskeletons (Thermo Electron). Images were collected on a TCS-S2 SP2 AORs confocal microscope (Leica Microsystems) using a ×63 oil immersion objective aperture 1.4 at different zoom factors. The confocal pinhole was set to 0.9 Airy units to ensure maximum resolution. FITC was excited using an argon laser at 488 nm, and DAPI, nuclear stain, was excited using a 405-nm diode laser (Coherent). Imaging fields were selected “blinded” in that the microscope was centered on the DAPI-stained nuclei and that field was imaged regardless of the presence or absence of MBP-Alexa Fluor 647-positive cells since Alexa Fluor 647 is far red and not visible to the eye.

Challenge of bmEos with PVM

PVM strain 15 was obtained from American Type Culture Collection and amplified in RAW264.7 cells (14) and stored in liquid nitrogen until use. Virus titer was determined by a quantitative RT-PCR assay that targets the unique virus SH gene as previously described (15). Before challenge of bmEos, PVM strain 15 was thawed and dialyzed against 1000 volumes of 0.5% BSA/PBS (pH 7.5) at 4°C to dilute cytokines elicited from the infected RAW264.7 cell culture. Following 10 days of ex vivo culture, bmEos were plated in fresh medium containing rmIL-5 at 10^5 cells/100 μl per well in 96-well plates. Cells were treated with equal volumes of virus (PVM), dialysis buffer, or heat-inactivated (HI) PVM (heated to 95°C and flash frozen in a dry ice-methanol bath three times). The cells and virus were incubated overnight at 32°C in a humidified 5% CO2 incubator. At the time points indicated, the culture medium was collected for analysis of secreted cytokines and RNA was collected for determination of virus copy number. The RNA was reverse transcribed as described above and used to determine absolute virus copy number. Absolute virus copy number was determined as described previously (15) with reference to a standard curve generated using serial 10-fold dilutions of the full SH gene as target. The cDNAs were then subjected to a second set of quantitative PCR assays to determine absolute GAPDH copy number. Absolute virus copy number is reported as copies of SH per 10^6 copies of GAPDH.

Cytokine measurement

Cytokine concentrations were determined using a multiplex bead assay (Lincoplex). Both a 16-plex and a 22-plex premixed bead assay yielded similar results. The assay was read on a Bioplex (Bio-Rad) plate reader and the values of the experimental data points were extrapolated from a standard curve generated by the instrument software using a five-parameter logistic method.

Chemotaxis assay

The assay was performed in a Transwell plate (Corning) with a 5.0-μm pore size polycarbonate membrane. Recombinant mouse eotaxin (R&D Systems) was dissolved in 0.5%BSA/PBS to 10 μg/ml and then further diluted in medium containing rmIL-5 until the concentrations used in the assay were achieved. One hundred microliters of the eotaxin-containing medium was placed in the lower well. One hundred microliters of bmEos at 500,000 cells/ml was placed in the upper chamber. Cells were incubated at 37°C for 3 h to permit migration across the membrane in response to the chemotactic agent. To ensure that the movement across the membrane was due to chemotaxis rather than chemokinesis, a series of experiments was performed in which there was no eotaxin gradient (eotaxin in the upper as well as lower chamber) and a control was included that contained no eotaxin at all. Data are presented as percentage of control (no eotaxin in either the top or bottom well), and data for both the bmEos exhibiting chemotaxis in response to the eotaxin gradient (eotaxin in the bottom well only) as well as those exhibiting chemokinesis (eotaxin in both wells) are shown.

Lentiviral transfection

The Vivid Colors pLenti6.2GW/EmGFp vector and the Virapower expression system (Invitrogen) were used to infect 293FT cells according to the manufacturer’s instructions. The resulting viral supernatant was collected and concentrated 100-fold by ultracentrifugation, and the viral titer was determined using a p24 ELISA kit (Cell-Biols). Day 3 bone marrow cultures were transduced with the lentivirus at a multiplicity of infection of 20 in the presence of 6 μg/ml polybrene (Invitrogen). The cultures were switched into medium containing rmIL-5 at day 4 and maintained as described above. At day 7 (4 days after transduction), GFP fluorescence was assessed with a fluorescence microscope (Leica DMIRBE2) at the Biological Imaging Section of the Research Technologies Branch (National Institute of Allergy and Infectious Diseases, Bethesda, MD) and by flow cytometry (FACSCalibur). Percent positive is based on total cell population, which is ~70% eosphilos at this time point.

Statistical analysis

Data sets were analyzed using Student’s t test unless otherwise indicated. All data are reported as the mean ± SEM.

Results

Cytokine-mediated differentiation of mouse bone marrow progenitors into eosinophils (bmEos)

Freshly isolated bone marrow progenitors are grown in rmSCF (100 ng/ml) and rmFLT3-L (100 ng/ml) for 4 days and in 10 ng/ml rmIL-5 thereafter (full details in Materials and Methods). Our culture yielded high-purity (~90%) bmEos by day 10 and thereafter (Fig. 1A) as determined by modified Giemsa staining (Fig. 1, B and C) and confirmed by expression of the cell surface Ag Siglec F (Fig. 1D). Total cell number increased >10-fold from the original 3 × 10^6 bone marrow cells to 36 ± 7 × 10^6 bmEos at day 17, with linear expansion observed primarily over days 8–15. The doubling
time is ∼48 h from days 4–12 (Fig. 1A). The stereotypical bilobed nucleus is featured in the Giemsa-stained bmEos in Fig. 1C; however, as can be seen in Fig. 1B, bmEos exhibit diverse nuclear morphologies, as do mouse eosinophils from peripheral blood (16). Confocal microscopy of bmEos (day 14 cultures) revealed pronounced staining of cytoplasmic granules with polyclonal anti-mouse (m) MBP Ab (mMBP, in red, Fig. 1E) as well as polymorphic nuclei characteristic of mature eosinophils (DAPI, in blue). No staining was seen in the secondary Ab only (data not shown). Interestingly, a fraction of phenotypically mature, granulated bmEos maintain the ability to undergo mitosis. Fig. 1F shows a bmEo in late anaphase. In addition to Siglec F (Fig. 1D), bmEos also express cell surface Ags IL5Rα (CD125), Gr-1, and CD11b (data not shown).

Expression of eosinophil transcripts

Relative expression of transcripts encoding eosinophil-specific and eosinophil-related genes was evaluated by quantitative RT-PCR.

FIGURE 3. bmEos exhibit chemotaxis toward recombinant mouse eotaxin-1. bmEos from day 10 cultures were used to measure chemotaxis in the presence of a mouse eotaxin-1 gradient (●), determined as percentage of cells migrating over control (no eotaxin); chemokinesis (migration measured in response to eotaxin-1 in both chambers) is indicated by □. Indistinguishable results were obtained using bmEos from day 12 cultures. Mean ± SEM of three separate cultures.
Relative expression of transcripts encoding mMBP, mEPO, and mCCR3 increased in differentiating bmEos and were all detected at ~50- to 100-fold over baseline at day 17 in culture. In contrast, expression of transcripts encoding mouse neutrophil myeloperoxidase (mMPO) decreased ~100-fold over the same interval (Fig. 2A). Similarly, by day 17 of culture, expression of transcripts encoding the IL-5R α-chain and the IL-3/IL-5/GM-CSF receptor βc both increased ~40- to 50 - fold over values detected in undifferentiated bone marrow progenitors (day 0). No change in expression was observed for transcripts encoding IL-3 and the GM-CSF receptor α-chains (Fig. 2B, note that the data points for IL-3Rα and GM-CSF receptor α-chains are superimposed). Finally, we observe ~100-fold elevated expression of the eosinophil-associated transcription factor GATA-1 at day 17, no change in expression of GATA-2, and prominent diminished expression of GATA-3 in from day 8 onward (Fig. 2C).

**Functional evaluation of bmEos**

Chemotactic responses of bmEos (day 10) were evaluated as shown in Fig. 3A. The percentage of bmEos that migrated along an established gradient of mouse eotaxin-1 (Fig. 3A, amount in lower chamber as shown on x-axis) was as indicated, with significant values above baseline (no gradient) detected at 100 and 1000 ng/ml eotaxin-1. Similar results were obtained using bmEos from day 12 cultures (data not shown). Furthermore, mouse bmEos spontaneously synthesize and release cytokines in a manner analogous to their natural counterparts (17). Cytokines IFN-γ, IL-4, IL-6, MIP-1α, IL-9 and IFN-γ-inducible protein 10 were all detected in supernatants of bmEos that had been washed and cultured for 24 h in rmIL-5 (Table I).

**Table I. Cytokines produced by bmEos**

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Concentration (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN-γ</td>
<td>15.3 ± 3.5</td>
</tr>
<tr>
<td>IL-4</td>
<td>218 ± 14</td>
</tr>
<tr>
<td>IL-6</td>
<td>20.0 ± 2.7</td>
</tr>
<tr>
<td>MIP-1α</td>
<td>268 ± 24</td>
</tr>
<tr>
<td>IL-9</td>
<td>31.2 ± 5.3</td>
</tr>
<tr>
<td>IL-10</td>
<td>396 ± 48</td>
</tr>
</tbody>
</table>

bmEos (10 days in culture) were plated at 10^6 cells/100 µl in fresh complete medium containing rmIL-5. After 24 h at 37°C, cytokine levels were assessed by multiplex bead analysis. Background (media only) was subtracted from the IFN-γ measurement; background for the other cytokine determinations was negligible.

**Discussion**

In this work, we demonstrate a means to generate large numbers of differentiated eosinophils (bmEos) at high purity from normal, unselected BALB/c mouse bone marrow progenitors. With this approach, progenitors are cultured for 4 days in rmSCF and rmFLT3-L and then in rmIL-5 alone thereafter. FLT3-L has been characterized as an agent that promotes the growth of primitive, highly proliferative progenitors (18) and SCF likewise supports progenitor growth, including specifically eosinophil progenitors (19). This method represents a substantial improvement over our previous culture system (12) which included IL-3 and GM-CSF in addition to the aforementioned cytokines. This latter regimen promotes substantial replication but yields only a small fraction of eosinophils. IL-3 and GM-CSF are perceived as promoting eosinophil differentiation more or less directly (20), as human peripheral blood and bone marrow progenitors can differentiate into eosinophils in the presence of IL-3 and GM-CSF in the absence of IL-5.
Finally, we found that differentiating bmEos can be transduced with the emGFPR containing lentiviral vector. This result suggests that lentivirus-mediated genetic alterations may be conducted in these ex vivo cultures, thereby clearing the way for the generation of large numbers of highly pure gene-manipulated eosinophils for reconstitution experiments. This method might also be used to explore the impact of specific gene manipulations on eosinophil development and differentiation.

In summary, we report here a means for the optimization of both yield and purity of mature eosinophils from unselected mouse bone marrow progenitors. The bmEos are fully differentiated when evaluated on the basis of morphology, molecular expression, and function. bmEos can be infected with and promote replication of the natural pneumovirus pathogen PVM, resulting in specific cytokine secretion. We plan to use bmEos- and lentivirus-mediated overexpression and/or silencing to understand eosinophil development and the interactions of eosinophils with respiratory virus pathogens in vitro and in vivo.

Acknowledgments
We thank Dr. Nancy A. Lee and Dr. James J. Lee for the generous gift of polyclonal anti-mouse anti-MBP Ab.

Disclosures
The authors have no financial conflict of interest.

References
36. Arnold, R., B. Konig, H. Galatti, H. Werchau, and W. Konig. 1995. Cytokine (IL-8, IL-6, TNF-α) and soluble TNF receptor-I release from human peripheral blood mononuclear cells after respiratory syncytial virus infection. Immunology 85: 364–372.